Blood Samples to Evaluate Biomarkers of Donor Chimerism

Fred Hutchinson Cancer Center80 enrolled

Overview

We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia Hodgkins Disease Non-hodgkins Lymphoma Myelodysplastic Syndrome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with a hematologic disease or malignancy * Scheduled to receive nonablative conditioning with fludarabine and total body irradiation * Donor is well-matched by high resolution DNA techniques. * Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an oral calcineurin inhibitor. * Age \>18 years at the time of enrollment. Exclusion criteria: -Diagnosed with an immunodeficiency disorder

Locations (1)

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Outcomes

Primary Outcomes

Donor T-cell chimerism

Time frame: Day 28 post-transplant

Secondary Outcomes

Exposure to fludarabine and mycophenolate mofetil and their breakdown products.

Time frame: Before and after transplant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.